A randomised phase 2a study to investigate the effects of blocking interleukin-33 with tozorakimab in patients hospitalised with COVID-19: ACCORD-2.

Thomas M A Wilkinson Anthony De Soyza Miles W Carroll James D ChalmersMichael G CrooksGareth GriffithsManu Shankar-HariLing-Pei HoAlex Robert HorsleyChris KellBeatriz Lara GallegoBiswa MishraRachel MoateClive PageHitesh PandyaJason RawFred ReidDinesh SaralayaIan C ScottSalman SiddiquiAndy UstianowskiNatalie van ZuydamAshley Woodcock Dave Singh

Published in: ERJ open research (2023)

Overall, ACCORD-2 results suggest that tozorakimab could be a novel therapy for patients hospitalised with COVID-19, warranting further investigation in confirmatory phase 3 studies.

Keyphrases

end stage renal disease
coronavirus disease
sars cov
ejection fraction
clinical trial
peritoneal dialysis
randomized controlled trial
patient reported outcomes
study protocol
community acquired pneumonia